Recently, Jiangsu Wanhai Medical Devices Co., Ltd. announced the completion of a financing round worth hundreds of millions, exclusively invested by IDG Capital, with Yuan Yi Capital serving as the exclusive financial advisor. This financing will assist Wanhai Medical in further expanding its annual production capacity from the existing 90 million units to 310 million units, forming a total production capacity of 400 million units for an automated and intelligent injection pen production base, further consolidating its leadership position in the global injection pen market.

Wanhai Medical was established in 2016, headquartered in Xitai Lake, Changzhou, Jiangsu Province, with a branch in Shanghai. It is a national high-tech enterprise and a specialized and innovative enterprise. The company focuses on the research, development, production, and sales of various types of injection pen products. It currently has a factory area of 12,000 square meters and an annual sales revenue of hundreds of millions, serving over 180 customers globally, with business operations in more than 60 countries and regions. The company has more than 300 employees, including over 50 in the R&D team and 12 in the registration team. Wanhai holds over 50 product patents and has more than 30 product quality testing reports issued by third-party testing institutions. The core product patents have been ensured to be free of infringement risks for global sales through FTO searches conducted by a well-known patent agency. Wanhai has obtained CE certification from TÜV SÜD, ISO13485 certification, as well as domestic Class II medical device registration certificates, production licenses, and business filing certificates, and has completed national drug packaging material registration. The company is currently applying for FDA certification in the United States, which is expected to be completed by early 2026.

The demand for chronic disease management has given rise to the golden path of injection pens.

Chronic diseases such as diabetes and obesity have long been significant health threats to the public. At the recent press conference on people's livelihoods during the third session of the 14th National People's Congress, Lei Haichao, the director of the National Health Commission, emphasized the continuous promotion of the "Weight Management Year" initiative, urging the government, industry, institutions, and individuals to fulfill their responsibilities, and to continue effective knowledge dissemination on chronic disease prevention and weight management, while emphasizing the integration of prevention and treatment. GLP-1 receptor agonists have gained widespread application globally due to their remarkable efficacy in treating diabetes, obesity, and chronic diseases. In 2024, the global sales of Novo Nordisk's semaglutide alone are expected to approach $30 billion, and it is anticipated to become the world's top-selling drug by 2025.

The injection pen market has historically been dominated by foreign companies such as Switzerland's Ypsomed, Germany's Haselmeier, and Taiwan's SHL. Additionally, insulin giants like Novo Nordisk and Eli Lilly also have their own production capacity for injection pens. However, imported injection pens are often expensive, with the price of reusable injection pens ranging from tens to hundreds of yuan, and single-use injection pens priced between 12 to 20 yuan. The high cost of imported injection pens has become a significant factor limiting the accessibility of chronic disease medications. To effectively reduce the burden of medical expenses, China began including insulin in centralized procurement in 2021, which has provided a development opportunity for domestic injection pen companies. Furthermore, the ongoing deepening of economic and trade cooperation in the pharmaceutical field under the "Belt and Road" Initiative, such as the official launch of the China-ASEAN pharmaceutical regional procurement platform this January, has also opened up new opportunities for China's pharmaceutical procurement to "go global." More and more overseas countries are beginning to pay attention to the cost-effectiveness of medications and improving drug accessibility, which gives high-quality and cost-effective domestic companies a new chance to stand on the global stage.

Currently, Wanhai Medical has a stable production capacity of 90 million disposable and reusable injection pens per year, forming a vertically integrated industrial chain layout from mold manufacturing, injection processing, automated assembly to testing and inspection. The company has nearly 30 various mold production and processing equipment, mainly from Japan's Makino and Sodick. In terms of injection molding, the company owns nearly 70 high-end imported electric injection molding machines from Japan's Sumitomo Demag and Sodick, with raw material suppliers being global top brands. For assembly, the company has established multiple automated production lines and semi-automatic equipment, equipped with a cleanroom of class 100, and currently has a daily output capacity of 300,000 units. Additionally, the company is equipped with Hexagon coordinate measuring machines, Mitutoyo and Nikon optical measuring instruments, as well as high-precision analytical balances of class 10 and class 100, ensuring that the precision of the produced injection pens meets ISO 11608 requirements.

After nearly a decade of rapid growth, Wanhai Medical has achieved sales of hundreds of millions of RMB, with customers in over 60 countries and regions and more than 180 clients, including several top biopharmaceutical companies both domestically and internationally, such as Tonghua Dongbao and Biocon, India’s largest biopharmaceutical company, along with a number of other outstanding international partners. To better support domestic and international clients in scaling up major products such as insulin and GLP-1, Wanhai continuously reduces product costs through large-scale production and process optimization.

Composition of Injection Pen and Injection Molding Parts

The main components of the injection pen include the pen cap, pen body, pen core, pen core holder, spiral piston rod, knob, and injection push button.

Requirements for materials of injection pens

Common Material Categories and Upstream Suppliers for Injection Pens